REDWOOD CITY, Calif., April 27, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced the acceptance of two abstracts at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO). The 2022 ASCO Annual Meeting will be held June 3-7, 2022 at McCormick Place in Chicago, IL.

The titles of abstracts accepted by Biomea are listed below. Biomea will disclose additional information about submissions in accordance with the American Society of Clinical Oncology’s abstract embargo policies.

Accepted ASCO 2022 Abstract Titles

• Preclinical activity of the irreversible Menin inhibitor, BMF-219, in chronic lymphocytic leukemia

• COVALENT-101: A Phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma ( DLBCL) and multiple myeloma (MM)

About Biomea Fusion

Biomea Fusion is a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond with its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, reduced drug exposure, and the ability to drive a deeper and longer lasting protein. answer. The company uses its proprietary FUSION™ system to advance a pipeline of covalently bonded therapeutics against major oncogenic factors in cancer and metabolic disease. Biomea Fusion’s goal is to use its capabilities and platform to become a leader in the development of covalent small molecules to maximize clinical benefits when treating various cancers and metabolic diseases.

The story continues

Forward-looking statements

Statements we make in this press release may include statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”). ), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements can be identified by words such as “aims”, “anticipates”, “believes”, “could”, “estimates”, “expects”, “plans”, “aims”, “intends”. of”, “may”, “plans”, “possible”, “potential”, “seeks”, “will” and variations of these words or similar expressions which are intended to identify forward-looking statements. All such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-219, the potential of BMF-219 as a treatment for various types of cancer and diabetes, our research, development and regulatory plans, the progress of our COVALENT-101 Phase I clinical trial and the timing of these events may be considered forward-looking statements. . We intend that these forward-looking statements be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Foreign Exchange Act and make this statement in purpose of complying with these safe harbor provisions.

All forward-looking statements contained in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ. significantly and unfavorably from those established. in or implied by these forward-looking statements, including the risk that we may face delays in recruiting patients and in initiating, conducting and completing our planned clinical trials and other research and development. These risks relating to Biomea Fusion’s business and operations are more fully described in its periodic filings with the United States Securities and Exchange Commission (the “SEC”), including its most recent periodic report filed with the SEC and subsequent subsequent filings. Biomea Fusion expressly disclaims any obligation to update forward-looking statements, except as required by law.

Contact:

Van Sandwick
Director, Investor Relations and Corporate Development
[email protected]
(650) 460-7759